scholarly journals Abstract No. 508 Locoregional control of painful spine metastatic lesions after percutaneous radiofrequency ablation and vertebral augmentation

2020 ◽  
Vol 31 (3) ◽  
pp. S223
Author(s):  
J. Marlow ◽  
J. Jennings
Keyword(s):  
Radiofrequency Ablation ◽  
Locoregional Control ◽  
Vertebral Augmentation ◽  
Percutaneous Radiofrequency Ablation ◽  
Metastatic Lesions ◽  
Painful Spine

scholarly journals The Role of a Navigational Radiofrequency Ablation Device and Concurrent Vertebral Augmentation for Treatment of Difficult-to-Reach Spinal Metastases

2021 ◽  
Vol 28 (5) ◽  
pp. 4004-4015
Author(s):  
Claudio Pusceddu ◽  
Davide De Francesco ◽  
Luca Melis ◽  
Nicola Ballicu ◽  
Alessandro Fancellu
Keyword(s):  
Radiofrequency Ablation ◽  
Pain Relief ◽  
Spinal Metastases ◽  
Local Tumor Control ◽  
Tumor Control ◽  
Vertebral Augmentation ◽  
Local Tumor ◽  
Metastatic Lesions ◽  
The Mean

Aims: The purpose of this study was to assess the effectiveness of a navigational radiofrequency ablation device with concurrent vertebral augmentation in the treatment of posterior vertebral body metastatic lesions, which are technically difficult to access. Primary outcomes of the study were evaluation of pain palliation and radiologic assessment of local tumor control. Materials and Methods: Thirty-five patients with 41 vertebral spinal metastases involving the posterior vertebral body underwent computed tomography-guided percutaneous targeted radiofrequency ablation, with a navigational radiofrequency ablation device, associated with vertebral augmentation. Twenty-one patients (60%) had 1 or 2 metastatic lesions (Group A) and fourteen (40%) patients had multiple (>2) vertebral lesions (Group B). Changes in pain severity were evaluated by visual analog scale (VAS). Metastatic lesions were evaluated in terms of radiological local control. Results: The procedure was technically successful in all the treated vertebrae. Among the symptomatic patients, the mean VAS score dropped from 5.7 (95% CI 4.9–6.5) before tRFA and to 0.9 (95% CI 0.4–1.3) after tRFA (p < 0.001). The mean decrease in VAS score between baseline and one week follow up was 4.8 (95% CI 4.2–5.4). VAS decrease over time between one week and one year following radiofrequency ablation was similar, suggesting that pain relief was immediate and durable. Neither patients with 1–2 vertebral metastases, nor those with multiple lesions, showed radiological signs of local progression or recurrence of the tumor in the index vertebrae during a median follow up of 19 months (4–46 months) and 10 months (4–37 months), respectively. Conclusion: Treatment of spinal metastases with a navigational radiofrequency ablation device and vertebral augmentation can be used to obtain local tumor control with immediate and durable pain relief, providing effective treatment in the multimodality management of difficult-to-reach spinal metastases.

scholarly journals Radiographic Local Control of Spinal Metastases with Percutaneous Radiofrequency Ablation and Vertebral Augmentation

2015 ◽  
Vol 37 (4) ◽  
pp. 759-765 ◽  
Author(s):  
A.N. Wallace ◽  
A. Tomasian ◽  
D. Vaswani ◽  
R. Vyhmeister ◽  
R.O. Chang ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Local Control ◽  
Spinal Metastases ◽  
Vertebral Augmentation ◽  
Percutaneous Radiofrequency Ablation

Effectiveness of percutaneous radiofrequency ablation for metachronous liver metastases of gastric cancer.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 136-136
Author(s):  
Jun-Eul Hwang ◽  
Dae-Eun Kim ◽  
Hyun-Jeong Shim ◽  
Woo Kyun Bae ◽  
Sang-Hee Cho ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Radiofrequency Ablation ◽  
Liver Metastases ◽  
Systemic Chemotherapy ◽  
Percutaneous Radiofrequency Ablation ◽  
Free Survival ◽  
Negatively Associated ◽  
Metastatic Lesions ◽  
Tumor Number

136 Background: This study evaluated the efficacy of percutaneous radiofrequency ablation (RFA) for the treatment of metachronous liver metastases of gastric cancer. Methods: We enrolled a total of 44 patients who underwent RFA for the treatment of metachronous liver metastases after resection of a primary gastric adenocarcinoma from January 2002 to November 2011. The primary endpoint of this study was overall survival (OS) and recurrence-free survival (RFS) after RFA. Results: Systemic chemotherapy was combined with RFA in 40 patients.The OS and RFS after RFA for all patients were 14.7 (95% CI, 10.1-19.2) and 6.1 months (95%, CI 4.2-8.1). the OS and RFS of the patients with liver-only metastasis who underwent RFA and chemotherapy were 20.9 months (95% CI 18.4-23.4) and 9.8 months (95% CI 9.2-10.5), respectively. On multivariate analysis, the factors independently, negatively associated with RFS were bilobar intrahepatic distribution (HR 3.9, 95% CI 1.5-9.9, p=0.001), and extrahepatic metastatic lesions (HR 3.6, 95% CI 1.6-7.8, p=0.003). The factors independently, negatively associated with OS were extrahepatic metastatic lesions (HR 12.6, 95% CI 3.7-42.9, p=0.001), no chemotherapy (HR 43.3, 95% CI 7.4-251.3, p=0.001), and tumor number (≥ 2) (HR 2.6, 95% CI 1.2-5.9, p=0.015). Conclusions: The efficacy of RFA for metachronous liver metastases of gastric cancer is limited to patients with a single, unilobar metastasis without extrahepatic metastatic lesions. Combined systemic chemotherapy is very important for the prolongation of overall survival.

Leberzellkarzinom – Radiofrequenzablation: Welches Bildgebungsverfahren ist effektiver?

2019 ◽  
Vol 24 (04) ◽  
pp. 163-164
Author(s):  
Cornelia Fietz
Keyword(s):  
Computed Tomography ◽  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Comparative Effectiveness ◽  
Percutaneous Radiofrequency Ablation ◽  
Ultrasound Guided ◽  
Medicare Patients ◽  
Us Dollar

Huo J et al. Comparative Effectiveness of Computed Tomography-Versus Ultrasound-Guided Percutaneous Radiofrequency Ablation Among Medicare Patients 65 Years of Age or Older With Hepatocellular Carcinoma. Value Health 2019; 22(3):284–292 Die Inzidenz des Leberzellkarzinoms hat sich in den letzen 20 Jahren mehr als verdoppelt. 2018 wurden in den USA mehr als 31 600 neue Fälle registriert, knapp die Hälfte dieser Patienten war älter als 65 Jahre. Die damit verbundenen jährlichen Kosten werden auf 455 Millionen US Dollar geschätzt. Für fortgeschrittene, inoperable Fälle steht die Radiofrequenzablation als Therapieoption zur Verfügung, die Ultraschall- oder Computertomographie-gestützt durchgeführt werden kann. Die Autoren vergleichen die Effektivität beider Bildgebungstechniken für das Verfahren.

Sign in / Sign up

Export Citation Format

Share Document